NASDAQ:EGRXEagle Pharmaceuticals Stock Price, Forecast & News

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EGRX shares have increased by 32.9% and is now trading at $51.92. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eagle Pharmaceuticals.

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eagle Pharmaceuticals.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.62. The specialty pharmaceutical company earned $46.02 million during the quarter, compared to analyst estimates of $47.76 million. Eagle Pharmaceuticals had a return on equity of 8.11% and a net margin of 1.29%. View Eagle Pharmaceuticals' earnings history.

2 brokers have issued 1-year price objectives for Eagle Pharmaceuticals' shares. Their forecasts range from $46.00 to $59.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $52.50 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View analysts' price targets for Eagle Pharmaceuticals.

Media headlines about EGRX stock have trended extremely negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutEagle Pharmaceuticals.

Some companies that are related to Eagle Pharmaceuticals include Uniqure (QURE), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Intercept Pharmaceuticals (ICPT), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX) and Prestige Consumer Healthcare (PBH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG), Clovis Oncology (CLVS), Horizon Therapeutics (HZNP) and Neurocrine Biosciences (NBIX).

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.86%), BlackRock Inc. (12.22%), Park West Asset Management LLC (9.02%), State Street Corp (4.57%), Invesco Ltd. (2.37%) and Tang Capital Management LLC (1.87%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View institutional ownership trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Janus Henderson Group PLC, AJO LP, Morgan Stanley, Morgan Stanley, Squarepoint Ops LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Eagle Pharmaceuticals.

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Schroder Investment Management Group, Matarin Capital Management LLC, Aviva PLC, Acadian Asset Management LLC, Park West Asset Management LLC, Pictet Asset Management Ltd., and Engineers Gate Manager LP. View insider buying and selling activity for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $51.92.

Eagle Pharmaceuticals has a market capitalization of $710.53 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]